These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 31141894)

  • 1. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
    Collins DM; Conlon NT; Kannan S; Verma CS; Eli LD; Lalani AS; Crown J
    Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Chilà G; Guarini V; Galizia D; Geuna E; Montemurro F
    Drug Des Devel Ther; 2021; 15():2711-2720. PubMed ID: 34188449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib for the treatment of breast cancer.
    Prové A; Dirix L
    Expert Opin Pharmacother; 2016 Nov; 17(16):2243-2248. PubMed ID: 27690680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
    Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.
    Batoo S; Bayraktar S; Al-Hattab E; Basu S; Okuno S; Glück S
    J Carcinog; 2019; 18():5. PubMed ID: 31949426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Friedecky D; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):281-8. PubMed ID: 21293538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer.
    Untch M; Martin M; De Laurentiis M; Gligorov J
    Oncol Ther; 2021 Dec; 9(2):297-309. PubMed ID: 34057699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of neratinib in HER2-driven breast cancer.
    Cherian MA; Ma CX
    Future Oncol; 2017 Sep; 13(22):1931-1943. PubMed ID: 28665682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.
    Segovia-Mendoza M; González-González ME; Barrera D; Díaz L; García-Becerra R
    Am J Cancer Res; 2015; 5(9):2531-61. PubMed ID: 26609467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
    Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
    Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.